We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The company’s goal is to offer reduced dose frequency compared to immediate-release carbidopa/levodopa, the gold standard for treatment since the 1970s. Read More
In the midst of a pandemic, if you wait for all the data to come in, “you’ve missed the boat,” said FDA Commissioner Robert Califf yesterday regarding the agency authorizing both Pfizer/BioNTech’s and Moderna’s bivalent COVID-19 boosters before any clinical trials on them are complete. Read More
U.S. sales of arformoterol tartrate inhalation solution reached an estimated $104 million for the 12-month period ending June 2022, according to healthcare analytics firm IQVIA. Read More